I agree to a point. So many posts have talked about would a new formulation require a whole new set of trials. If the answer is no because,it has the same active ingredients then it opens up a possib.e problem with pbm and insurance companies. They could easily substitute the generic for new V since it basically the same drug. A few other comments on new form. I do not agree that they cant announce plans for a new formulation because of competitive reasons. Every othe drug company lists every trial and pre trial drugs on their website. If they announced it who is the competitor that is going to gain an upper hand. But also in the other direction I feel something is going on because they are not doing the buyback preserving the cash for something
Market Data 
Markets 
AI
